LncRNA HOXA10-AS functions as an oncogene by binding miR-6509-5p to upregulate Y-box binding protein 1 in gastric cancer

被引:7
|
作者
Li, Shanshan [1 ]
Lu, Chuanhui [2 ,3 ]
Li, Xinyu [4 ]
Li, Fan [2 ,3 ]
Zhao, Yunfeng [5 ]
Xu, Meimei [1 ]
Jia, Hongyu [1 ]
Yuan, Sibo [6 ,7 ]
机构
[1] First Hosp Qinhuangdao, Dept Gastroenterol, 258 Wenhua Rd, Qinhuangdao 066000, Hebei, Peoples R China
[2] Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Colorectal Canc Surg, Xiamen 361003, Fujian, Peoples R China
[3] Fujian Med Univ, Clin Med Coll 3, Dept Colorectal Canc Surg, Fuzhou 350108, Fujian, Peoples R China
[4] Fujian Med Univ, Dept Gastrointestinal Surg, Quanzhou Hosp 1, Quanzhou 362002, Fujian, Peoples R China
[5] First Hosp Qinhuangdao, Dept Cardiovasc Internal Med CCU Ward, Qinhuangdao 066000, Hebei, Peoples R China
[6] Xiamen Univ, Zhongshan Hosp, Dept Gastrointestinal Surg, 201 Hubin South Rd, Xiamen 361000, Fujian, Peoples R China
[7] Xiamen Univ, Xiamen City Key Lab Gastrointestinal Canc, Zhongshan Hosp, 201 Hubin South Rd, Xiamen 361000, Fujian, Peoples R China
关键词
Gastric cancer; LncRNA HOXA10-AS; miR-6509-5p; Y-box binding protein 1; RNA;
D O I
10.1080/21655979.2022.2059615
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Gastric cancer (GC) is one of the serious malignant diseases, accounting for several cases globally. The prevention, discovery and cure of GC depend on its molecular mechanism. In recent decades, it has been increasingly recognized that the long noncoding RNAs (lncRNAs) have been involved in GC progression. Therefore, the present study is aimed at identifying relevant lncRNAs that could act as biomarkers for GC prognosis. LncRNA HOXA10-AS is identified to be highly expressed in GC using the ENCORI database. Kaplan-Meier plot analysis indicated that the survival rate of the patient is associated with the expression of lncRNA HOXA10-AS. Interference of HOXA10-AS inhibited GC cell proliferation, migration, and invasion as well as facilitated GC apoptosis. The targets of HOXA10-AS included miR-6509-5p and Y-box binding protein 1 (YBX1). Specifically, HOXA10-AS downregulated miR-6509-5p in GC. An increase of miR-6509-5p inhibited GC cell growth. Meanwhile, miR-6509-5p interacted with YBX1 in GC. Together, lncRNA HOXA10-AS potentially acted as an oncogene through the lncRNA HOXA10-AS/miR-6509-5p/YBX1 signaling pathway in GC.
引用
收藏
页码:11373 / 11387
页数:15
相关论文
共 50 条
  • [41] FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer
    Imada, Kenjiro
    Shiota, Masaki
    Kuroiwa, Kentaro
    Sugimoto, Masaaki
    Abe, Tatsuro
    Kohashi, Kenichi
    Yokomizo, Akira
    Eto, Masatoshi
    Naito, Seiji
    Oda, Yoshinao
    PROSTATE, 2017, 77 (02): : 145 - 153
  • [42] Alteration of Y-box Binding Protein-1 Expression Modifies the Response to Endocrine Therapy in Estrogen Receptor Positive Breast Cancer.
    Ito, T.
    Kamijo, S.
    Izumi, H.
    Kohno, K.
    Ito, K-I
    CANCER RESEARCH, 2011, 71
  • [43] Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer
    Ito, Tokiko
    Kamijo, Shinobu
    Izumi, Hiroto
    Kohno, Kimitoshi
    Amano, Jun
    Ito, Ken-ichi
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (01) : 145 - 159
  • [44] Y-BOX BINDING PROTEIN-1 ACTIVATION MAY MODIFY THE RESPONSES TO ENDOCRINE AND HER2-TARGETED THERAPEUTICS IN BREAST CANCER
    Kuwano, Michihiko
    Shibata, Tomohiro
    Kawahara, Akihiko
    Hattori, Satoshi
    Takahashi, Ryuji
    Watari, Kosuke
    Murakami, Yuichi
    Izumi, Hiroto
    Kage, Masayoshi
    Ono, Mayumi
    ANNALS OF ONCOLOGY, 2014, 25
  • [45] Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer
    Tokiko Ito
    Shinobu Kamijo
    Hiroto Izumi
    Kimitoshi Kohno
    Jun Amano
    Ken-ichi Ito
    Breast Cancer Research and Treatment, 2012, 133 : 145 - 159
  • [46] P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance
    Shiota, Masaki
    Yokomizo, Akira
    Tada, Yasuhiro
    Uchiumi, Takeshi
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Kuroiwa, Kentaro
    Yamamoto, Ken
    Seki, Narihito
    Naito, Seiji
    CANCER SCIENCE, 2010, 101 (08) : 1797 - 1806
  • [47] Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells
    Juerchott, Karsten
    Kuban, Ralf-Juergen
    Krech, Till
    Bluthgen, Nils
    Stein, Ulrike
    Walther, Wolfgang
    Friese, Christian
    Kielbasa, Szymon M.
    Ungethuem, Ute
    Lund, Per
    Knoesel, Thomas
    Kemmner, Wolfgang
    Morkel, Markus
    Fritzmann, Johannes
    Schlag, Peter M.
    Birchmeier, Walter
    Krueger, Tammo
    Sperling, Silke
    Sers, Christine
    Royer, Hans-Dieter
    Herzel, Hanspeter
    Schaefer, Reinhold
    PLOS GENETICS, 2010, 6 (12): : 1 - 19
  • [48] The antiestrogens 4-hydroxytamoxifen and fulvestrant are inhibitors of oncogenic factor Y-box binding protein-1 expression in breast cancer cells
    Stope, M. B.
    Popp, S. L.
    Joffroy, C.
    Mustea, A.
    Buck, M. B.
    Knabbe, C.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 764 - 768
  • [49] YB1/p32, a nuclear Y-box binding protein 1, is a novel regulator of myoblast differentiation that interacts with Msx1 homeoprotein
    Song, Young Joon
    Lee, Hansol
    EXPERIMENTAL CELL RESEARCH, 2010, 316 (04) : 517 - 529
  • [50] Increased Nuclear Localization of Transcription Factor Y-Box Binding Protein 1 Accompanied by Up-Regulation of P-Glycoprotein in Breast Cancer Pretreated with Paclitaxel.
    Fujita, T.
    Nagura, N.
    Koshikawa, K.
    Nishimura, H.
    Ito, K-I
    Izumi, H.
    Kohno, K.
    Fujimori, M.
    CANCER RESEARCH, 2009, 69 (24) : 583S - 584S